Archivos de autor

Dr. Julian López Pérez.

Ginecólogo- Obstetra
Enfermedades de la Mujer, embarazos, partos. Cirugía ginecológica. Menopausia.
Girona.
Clínica Girona Tlf. 972 483 535
Clínica Onyar: Tlf 972 204 900
Previa cita
Contacto: drjulian@gineonline.com

AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VYLEESI™ (BREMELANOTIDE INJECTION) FOR ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN – AMAG Pharmaceuticals

AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF VYLEESI™ (BREMELANOTIDE INJECTION) FOR ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN – AMAG Pharmaceuticals — Leer en http://www.amagpharma.com/news/amag-pharmaceuticals-announces-fda-approval-of-vyleesi-bremelanotide-injection-for-acquired-generalized-hypoactive-sexual-desire-disorder-hsdd-in-premenopausal-women/ Nuevo fármaco aprobado para el deseo sexual hipoactivo, por la FDA. Próxima comercialización, su mecanismo de acción no está bien establecido, pero parece […]

Is HPV screening for cervical cancer predictive of risk of anal cancer? | Contemporary OBGYN

A new systematic review sheds light on whether routine cervical cancer screening results might predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL), and anal cancer — Leer en http://www.contemporaryobgyn.net/hpv/hpv-screening-cervical-cancer-predictive-risk-anal-cancer HPV 16 + en el screening de cuello uterino, se puede relacionar con riesgo aumentado de cáncer anal…